Myriad loses some private insurance coverage for BRCA tests; Atossa Genetics adopts M&A poison pill;

> Horizon Blue Cross Blue Shield of New Jersey and Amerigroup have separately told providers in their networks to stop using Myriad Genetics ($MYGN) for BRCA diagnostic testing. Story (reg. req.)

> Atossa Genetics ($ATOS), under fire for allegedly making misleading claims about its breast cancer test, has adopted a poison pill to fend off unwanted suitors. Story

> BioTime ($BTX) subsidiary OncoCyte has sealed a licensing deal with Weill Cornell Medical College to accelerate lung cancer diagnostic product development. Release

> A new esophageal cancer biomarker is showing some potential in helping to screen for the disease and early scarring that can lead to it. Story

> PerkinElmer ($PKI) said it will distribute Sebia's newborn blood screening test globally. Item (req. req.)

> Researchers have identified a new biomarker for oxidative stress generated during exercise, a physical response thought to be linked to some cancers, heart disease, Alzheimer's disease and other illnesses. Item

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.